Source Multiple Sclerosis News Today: T20K, Cyxone‘s lead compound for treating multiple sclerosis (MS), seems able to prevent or slow disease progression, according to data from preclinical studies. Based on these findings, the company is confident that T20K might become a prophylactic (preventive) medication for MS in the near future.
Source Multiple Sclerosis News Today: T20K, Cyxone‘s lead compound for treating multiple sclerosis (MS), seems able to prevent or slow disease progression, according to data from preclinical studies. Based on these findings, the company is confident that T20K might become a prophylactic (preventive) medication for MS in the near future.
T20K is a unique compound derived from a plant protein. Researchers from the Medical University of Vienna (Austria) and the University Medical Center in Freiburg (Germany) were the first to show that T20K was able to block the activity of pro-inflammatory cytokines (molecules that mediate immune and inflammatory responses), such as interleukin-2 (IL-2), and reduce symptoms of MS in animal models of the disease without toxic side effects. Read on.
